Incidence of Postoperative Chylothorax Following Congenital Heart Surgery in Pediatric Patients: A Single-Center Experience

Authors

  • Sung Kwang Lee, MD Department of Thoracic and Cardiovascular Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University college of Medicine, Pusan National University Yangsan Hospital
  • Kwang Ho Choi, MD Department of Thoracic and Cardiovascular Surgery, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University college of Medicine, Pusan National University Yangsan Hospital

DOI:

https://doi.org/10.1532/hsf.3043

Keywords:

congenital heart disease, postoperative complications, chylothorax

Abstract

Background: Although postoperative chylothorax following congenital heart surgery occurs rarely, it is associated with substantial morbidity and mortality. The incidence of postoperative chylothorax has been reported as 2% to 5%. Therefore, we aimed to evaluate the incidence of postoperative chylothorax at our center and compared our results with those of other studies.

Methods: Between January 2009 and December 2018, there were 2,515 congenital heart repair surgeries performed at our center. Thirty-six patients with postoperative chylothorax were enrolled in this study, and their medical records retrospectively were reviewed. We calculated the overall and surgery-specific incidences. We compared the data of the medical management group with those of the surgical management group.

Results: The overall incidence of postoperative chylothorax was 1.4%. The incidence was highest for patients who underwent vascular ring repair (3/32). Moreover, the incidence was higher for single ventricle-related procedure than bi-ventricle-related procedures (5.6% versus 1.0%, P < .0001). Chylothorax was predominantly found on the left side (20/36). Among these cases, six patients died; three of these six were in the surgical management group.

Conclusions: The postoperative chylothorax incidence at our center was comparable to those of other centers. However, a reasonable protocol for postoperative chylothorax management to improve outcomes is necessary.

References

Bang JH, Kim SH, Park CS, Park JJ, Yun TJ. 2015. Anatomic variability of the thoracic duct in pediatric patients with complex congenital heart disease. The Journal of thoracic and cardiovascular surgery. Sep;150(3):490-5.

Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. 2000. Etiology and management of pediatric chylothorax. The Journal of pediatrics. May;136(5):653-8.

Buchwald MA, Laasner U, Balmer C, Cannizzaro V, Latal B, Bernet V. 2018. Comparison of postoperative chylothorax in infants and children with trisomy 21 and without dysmorphic syndrome: Is there a difference in clinical outcome? Journal of pediatric surgery. Jul 6.

Buckley JR, Graham EM, Gaies M, et al. 2017. Clinical epidemiology and centre variation in chylothorax rates after cardiac surgery in children: a report from the Pediatric Cardiac Critical Care Consortium. Cardiology in the young. May 29:1-8.

Chalret du Rieu M, Baulieux J, Rode A, Mabrut JY. 2011. Management of postoperative chylothorax. J Visc Surg. Oct;148(5):e346-52.

Chan EH, Russell JL, Williams WG, Van Arsdell GS, Coles JG, McCrindle BW. 2005. Postoperative chylothorax after cardiothoracic surgery in children. The Annals of thoracic surgery. Nov;80(5):1864-70.

Chen E, Itkin M. 2011. Thoracic duct embolization for chylous leaks. Semin Intervent Radiol. Mar;28(1):63-74.

Chen H, Shoumura S, Emura S. 2006. Bilateral thoracic ducts with coexistent persistent left superior vena cava. Clin Anat. May;19(4):350-3.

Christofe NM, Pessotti CFX, Paiva L, Jatene IB. 2017. Incidence and Treatment of Chylothorax in Children Undergoing Corrective Surgery for Congenital Heart Diseases. Brazilian journal of cardiovascular surgery. Sep-Oct;32(5):390-393.

Cummings SP, Wyatt DA, Baker JW, et al. 1992. Successful treatment of postoperative chylothorax using an external pleuroperitoneal shunt. Ann Thoracic Surg 4:276-8.

Czobor NR, Roth G, Prodan Z, et al. 2017. Chylothorax after pediatric cardiac surgery complicates short-term but not long-term outcomes-a propensity matched analysis. Journal of thoracic disease. Aug;9(8):2466-2475.

Day TG, Zannino D, Golshevsky D, d'Udekem Y, Brizard C, Cheung MMH. 2018. Chylothorax following paediatric cardiac surgery: a case-control study. Cardiology in the young. Feb;28(2):222-228.

Efrati O, Barak A. 2002. Pleural effusions in the pediatric population. Pediatrics in review. Dec 23(12):417-26.

Haines C, Walsh B, Fletcher M, Davis PJ. 2014. Chylothorax development in infants and children in the UK. Archives of disease in childhood. Aug;99(8):724-30.

Higgins CB, Mulder DG. 1971. Chylothorax after surgery for congenital heart disease. The Journal of thoracic and cardiovascular surgery. Mar;61(3):411-8.

Hirata Y, Hirahara N, Murakami A, Motomura N, Miyata H, Takamoto S. 2018. Current status of cardiovascular surgery in Japan 2013 and 2014: A report based on the Japan Cardiovascular Surgery Database. 2: Congenital heart surgery. General thoracic and cardiovascular surgery. Jan;66(1):4-7.

Hoskote AU, Ramaiah RN, Cale CM, Hartley JC, Brown KL. 2012. Role of immunoglobulin supplementation for secondary immunodeficiency associated with chylothorax after pediatric cardiothoracic surgery. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. Sep;13(5):535-41.

Ismail SR, Kabbani MS, Najm HK, Shaath GA, Jijeh AM, Hijazi OM. 2014. Impact of chylothorax on the early postoperative outcome after pediatric cardiovascular surgery. J Saudi Heart Assoc. Apr;26(2):87-92.

Kwon SS, Falk A, Mitty HA. 2002. Thoracic duct injury associated with left internal jugular vein catheterization: anatomic considerations. J Vasc Interv Radiol. Mar;13(3):337-9.

Law MA, McMahon WS, Hock KM, Zaccagni HJ, Borasino S, Alten JA. 2015. Balloon Angioplasty for the Treatment of Left Innominate Vein Obstruction Related Chylothorax after Congenital Heart Surgery. Congenital heart disease. Jul-Aug;10(4):E155-63.

Liu CS, Tsai HL, Chin TW, Wei CF. 2005. Surgical treatment of chylothorax caused by cardiothoracic surgery in children. Journal of the Chinese Medical Association: JCMA. May; 68(5):234-6.

Lopez-Gutierrez JC, Tovar JA. 2014. Chylothorax and chylous ascites: management and pitfalls. Seminars in pediatric surgery. Oct;23(5):298-302.

Mery CM, Moffett BS, Khan MS, et al. 2014. Incidence and treatment of chylothorax after cardiac surgery in children: analysis of a large multi-institution database. The Journal of thoracic and cardiovascular surgery. Feb;147(2):678-86.e1; discussion 685-6.

Milsom JW, Kron IL, Rheuban KS, Rodgers BM. 1985. Chylothorax: an assessment of current surgical management. J Thoracic Cardiovasc Surg 89:221-7.

Nguyen DM, Shum-Tim D, Dobell AR, Tchervenkov CI. 1995. The management of chylothorax/chylopericardium following pediatric cardiac surgery: a 10-year experience. Journal of cardiac surgery. Jul;10(4 Pt 1):302-8.

Pego-Fernandes PM, Nascimbem MB, Ranzani OT, Shimoda MS, Monteiro R, Jatene FB. 2011. Video-assisted thoracoscopy as an option in the surgical treatment of chylothorax after cardiac surgery in children. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia. Jan-Feb;37(1):28-35.

Savla JJ, Itkin M, Rossano JW, Dori Y. 2017. Post-Operative Chylothorax in Patients With Congenital Heart Disease. Journal of the American College of Cardiology. May 16;69(19):2410-2422.

van der Putte SC, van Limborgh J. 1980. The embryonic development of the main lymphatics in man. Acta Morphol Neerl Scand. Dec;18(4):323-35.

Zuluaga MT. 2012. Chylothorax after surgery for congenital heart disease. Current opinion in pediatrics. Jun;24(3):291-4.

Published

2020-06-16

How to Cite

Lee, S. K., & Choi, K. H. (2020). Incidence of Postoperative Chylothorax Following Congenital Heart Surgery in Pediatric Patients: A Single-Center Experience. The Heart Surgery Forum, 23(4), E430-E434. https://doi.org/10.1532/hsf.3043

Issue

Vol. 23 No. 4 (2020)

Section

Articles

Author Disclosure & Copyright Transfer Agreement

In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.

A current form follows:

The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.

However, Publisher grants back to the author(s) the following:

  1. The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
  2. The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
  3. The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
  4. The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
  5. The right to make oral presentations of material from this work.

Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.

I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.

I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).

I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.

Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).